

Treg Cell-based Therapies FDA Approvals, MOA, ROA, Clinical Trials, Emerging Drugs | DelveInsight

Treg Cell-based Therapies Pipeline

LAS VEGAS, NV, UNITED STATES, February 5, 2025 /EINPresswire.com/ -- DelveInsight's, "Treg Cell-based Therapies Pipeline Insight" report provides comprehensive insights about 51+ companies and 55+ pipeline drugs in Treg Cell-based Therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

□ Stay ahead in the Treg Cell-based Therapies treatment landscape! Explore the latest breakthroughs, emerging therapies, and key players shaping the market. Download the report now! @ [Treg Cell-based Therapies Pipeline Outlook](#)

Key Takeaways from the Treg Cell-based Therapies Pipeline Report

- DelveInsight's Treg Cell-based Therapies pipeline report depicts a robust space with 51+ active players working to develop 55+ pipeline therapies for Treg Cell-based Therapies treatment.
- The leading Treg Cell-based Therapies Companies such as Orca Bio, Nektar Therapeutics, Quell Therapeutics, Cugene, Sangamo Therapeutics, Abata Therapeutics, HCW Biologics, GentiBio, Tr1X, PolTREG, Cellenkos, VT BIO, Miltenyi Biotec GmbH, KSQ Therapeutics, TerImmune and others.
- Promising Treg Cell-based Therapies Therapies such as Orca-T, NKTR-358, QEL-001, CUG-252, and others.

□ Unlock strategic insights into the evolving Treg Cell-based Therapies pipeline! Get in-depth analysis of clinical-stage developments and upcoming therapies. Access the full report today! @ [Treg Cell-based Therapies Clinical Trials](#)

Treg Cell-based Therapies Emerging Drugs Profile

- Orca-T: Orca Bio

Orca-T is an investigational high-precision allogeneic cellular therapy consisting of infusions containing regulatory T-cells, conventional T-cells and CD34+ stem cells derived from peripheral blood from either related or unrelated matched donors. Orca-T has received Regenerative

Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration and is being studied to treat multiple hematologic malignancies. Currently, the drug is in the Phase III stage of its development for the treatment of acute myeloid leukaemia, Myelodysplastic syndromes, Acute Lymphoid Leukemia, and Mixed Phenotype Acute Leukemia.

- NKTR-358: Nektar Therapeutics

NKTR-358 is a novel first-in-class regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions. NKTR-358 works by targeting the IL-2 receptor complex and preferentially stimulating the proliferation of Treg cells without stimulating cytotoxic CD8+ T and CD4+ T cells, which drive autoimmune disease. Activation of Tregs suppresses disease-causing T cells and restores the body's self-tolerance mechanisms. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with atopic dermatitis and Alopecia Areata.

- QEL-001: Quell Therapeutics

QEL-001 is a first-in-class antigen-specific CAR-Treg cell therapy candidate designed using Quell's unique multi-modular engineered Treg platform and engineered with three proprietary modules: a chimeric antigen receptor (CAR) for tissue targeting, the Foxp3 phenotype lock module, and a safety switch. The QEL-001 CAR is specific for HLA-A2, which localizes the activity of the CAR-Tregs to the site of the transplanted organ in HLA-A2 mismatch liver transplant patients. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of patients with Liver transplantation.

- CUG-252: Cugene

CUG-252, developed by Cugene is an interleukin-2 replacement. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with Atopic dermatitis, Inflammatory bowel diseases, Rheumatoid arthritis, and Systemic lupus erythematosus.

□ Gain a competitive edge in the Treg Cell-based Therapies market! Discover promising pipeline candidates, regulatory trends, and future treatment outlooks. Request your report now! @ [Treg Cell-based Therapies Unmet Needs](#)

Treg Cell-based Therapies Companies

Orca Bio, Nektar Therapeutics, Quell Therapeutics, Cugene, Sangamo Therapeutics, Abata Therapeutics, HCW Biologics, GentiBio, Tr1X, PolTREG, Cellenkos, VT BIO, Miltenyi Biotec GmbH, KSQ Therapeutics, Teralmmune and others.

Treg Cell-Based Therapies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Intravenous
- Subcutaneous
- Oral

- Intramuscular

Treg Cell-based Therapies Products have been categorized under various Molecule types such as

- Monoclonal antibody
- Small molecule
- Peptide

Dive into comprehensive Treg Cell-based Therapies pipeline analysis, key company strategies, and clinical advancements. Download DelveInsight's exclusive report! @ Treg Cell-based Therapies FDA Approvals and Pipeline Developmental Activities-

https://www.delveinsight.com/sample-request/treg-cell-based-therapies-pipeline-insight?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Treg Cell-based Therapies Pipeline Report

- Coverage- Global
- Treg Cell-based Therapies Companies- Orca Bio, Nektar Therapeutics, Quell Therapeutics, Cugene, Sangamo Therapeutics, Abata Therapeutics, HCW Biologics, GentiBio, Tr1X, PolTREG, Cellenkos, VT BIO, Miltenyi Biotec GmbH, KSQ Therapeutics, Teralmmune and others.
- Treg Cell-based Therapies Therapies- Orca-T, NKTR-358, QEL-001, CUG-252, and others.
- Treg Cell-based Therapies Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Treg Cell-based Therapies Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

□ Track the latest innovations in Treg Cell-based Therapies therapies! Stay informed on upcoming launches, trial results, and market dynamics. Get your copy of the report today! @ Treg Cell-based Therapies Market Drivers and Barriers, and Future Perspectives-

https://www.delveinsight.com/sample-request/treg-cell-based-therapies-pipeline-insight?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr

Table of Content

1. Introduction
2. Executive Summary
3. Treg Cell-Based Therapies: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Treg Cell-Based Therapies– DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Orca-T: Orca Bio
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. NKTR-358: Nektar Therapeutics

12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. CUG-252: Cugene
15. Drug profiles in the detailed report.....
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report.....
19. Inactive Products
20. Treg Cell-Based Therapies Key Companies
21. Treg Cell-Based Therapies Key Products
22. Treg Cell-Based Therapies- Unmet Needs
23. Treg Cell-Based Therapies- Market Drivers and Barriers
24. Treg Cell-Based Therapies- Future Perspectives and Conclusion
25. Treg Cell-Based Therapies Analyst Views
26. Treg Cell-Based Therapies Key Companies
27. Appendix

List of Top Selling Market Research Reports in 2025

Surgical Lasers Market - <https://www.delveinsight.com/report-store/surgical-lasers-market>

Intraocular Lens Market - <https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market>

Myeloproliferative Neoplasms Market - <https://www.delveinsight.com/report-store/myeloproliferative-neoplasms-market>

Skin Neoplasm Market - <https://www.delveinsight.com/report-store/nonmelanoma-skin-cancer-market>

Healthcare Competitive Benchmarking - <https://www.delveinsight.com/consulting/competitive-benchmarking-services>

Microscopy Device Market - <https://www.delveinsight.com/report-store/microscopy-device-market>

Pacemakers Market - <https://www.delveinsight.com/report-store/pacemakers-market>

Urea Cycle Disorders Market - <https://www.delveinsight.com/blog/urea-cycle-disorder-market>

Novel Drug Delivery Devices Market - <https://www.delveinsight.com/report-store/novel-drug-delivery-devices>

Nk Cell Therapy Market - <https://www.delveinsight.com/infographics/nk-cell-therapy-market>

Surgical Mask & Respirator Market - <https://www.delveinsight.com/report-store/surgical-mask-respirator-market>

Lymphoedema Market - <https://www.delveinsight.com/report-store/lymphoedema-market>

Phototherapies For Psoriasis Market - <https://www.delveinsight.com/report-store/phototherapy-devices-market>

Sepsis Market - <https://www.delveinsight.com/report-store/sepsis-market>

Bone Growth Stimulator Market - <https://www.delveinsight.com/report-store/bone-growth-stimulators-market>

Antibody Drug Conjugate Market - <https://www.delveinsight.com/report-store/antibody-drug-conjugate-market>

Overactive Bladder Syndrome Market - <https://www.delveinsight.com/report-store/underactive-bladder-market>

Medical Marijuana Market - <https://www.delveinsight.com/report-store/medical-marijuana-market>

Lactose Intolerance Market - <https://www.delveinsight.com/report-store/lactose-intolerance-market>

Catheter Stabilization Devices Market - <https://www.delveinsight.com/sample-request/catheter-stabilization-securement-device-market>

Dyspepsia Market - <https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight>

Total Knee Arthroplasty Market - <https://www.delveinsight.com/report-store/knee-reconstruction-devices-market>

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Yash Bhardwaj

DelveInsight

+91 9650213330

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/783209947>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.